

## Statement from specialists in nicotine science and public health policy

Dr Margaret Chan  
Director General  
World Health Organisation  
Geneva

CC: FCTC Secretariat, Parties to the FCTC, WHO Regional Offices

26 May 2014

Dear Dr Chan

### **Reducing the toll of death and disease from tobacco – tobacco harm reduction and the Framework Convention on Tobacco Control (FCTC)**

We are writing in advance of important negotiations on tobacco policy later in the year at the FCTC Sixth Conference of the Parties. The work of WHO and the FCTC remains vital in reducing the intolerable toll of cancer, cardiovascular disease and respiratory illnesses caused by tobacco use. As WHO has stated, up to one billion preventable tobacco-related premature deaths are possible in the 21st Century. Such a toll of death, disease and misery demands that we are relentless in our search for all possible practical, ethical and lawful ways to reduce this burden.

It is with concern therefore that a critical strategy appears to have been overlooked or even purposefully marginalised in preparations for FCTC COP-6. We refer to 'tobacco harm reduction' - the idea that the 1.3 billion people who currently smoke could do much less harm to their health if they consumed nicotine in low-risk, non-combustible form.

We have known for years that people 'smoke for the nicotine, but die from the smoke': the vast majority of the death and disease attributable to tobacco arises from inhalation of tar particles and toxic gases drawn into the lungs. There are now rapid developments in nicotine-based products that can effectively substitute for cigarettes but with very low risks. These include for example, e-cigarettes and other vapour products, low-nitrosamine smokeless tobacco such as snus, and other low-risk non-combustible nicotine or tobacco products that may become viable alternatives to smoking in the future. Taken together, these tobacco harm reduction products could play a significant role in meeting the 2025 UN non-communicable disease (NCD) objectives by driving down smoking prevalence and cigarette consumption. Indeed, it is hard to imagine major reductions in tobacco-related NCDs without the contribution of tobacco harm reduction. Even though most of us would prefer people to quit smoking and using nicotine altogether, experience suggests that many smokers cannot or choose not to give up nicotine and will continue to smoke if there is no safer alternative available that is acceptable to them.

We respectfully suggest that the following principles should underpin the public health approach to tobacco harm reduction, with global leadership from WHO:

## Statement from specialists in nicotine science and public health policy

1. *Tobacco harm reduction is part of the solution, not part of the problem.* It could make a significant contribution to reducing the global burden of non-communicable diseases caused by smoking, and do so much faster than conventional strategies. If regulators treat low-risk nicotine products as traditional tobacco products and seek to reduce their use without recognising their potential as low-risk alternatives to smoking, they are improperly defining them as part of the problem.
2. *Tobacco harm reduction policies should be evidence-based and proportionate to risk, and give due weight to the significant reductions in risk that are achieved when a smoker switches to a low risk nicotine product.* Regulation should be proportionate and balanced to exploit the considerable health opportunities, while managing residual risks. The architecture of the FCTC is not currently well suited to this purpose.
3. *On a precautionary basis, regulators should avoid support for measures that could have the perverse effect of prolonging cigarette consumption.* Policies that are excessively restrictive or burdensome on lower risk products can have the unintended consequence of protecting cigarettes from competition from less hazardous alternatives, and cause harm as a result. Every policy related to low risk, non-combustible nicotine products should be assessed for this risk.
4. *Targets and indicators for reduction of tobacco consumption should be aligned with the ultimate goal of reducing disease and premature death, not nicotine use per se, and therefore focus primarily on reducing smoking.* In designing targets for the non-communicable disease (NCD) framework or emerging Sustainable Development Goals it would be counterproductive and potentially harmful to include reduction of low-risk nicotine products, such as e-cigarettes, *within these targets*: instead these products should have an important role in *meeting the targets*.
5. *Tobacco harm reduction is strongly consistent with good public health policy and practice and it would be unethical and harmful to inhibit the option to switch to tobacco harm reduction products.* As the WHO's Ottawa Charter states: "*Health promotion is the process of enabling people to increase control over, and to improve, their health*". Tobacco harm reduction allows people to control the risk associated with taking nicotine and to reduce it down to very low or negligible levels.
6. *It is counterproductive to ban the advertising of e-cigarettes and other low risk alternatives to smoking.* The case for banning tobacco advertising rests on the great harm that smoking causes, but no such argument applies to e-cigarettes, for example, which are far more likely to reduce harm by reducing smoking. Controls on advertising to non-smokers, and particularly to young people are certainly justified, but a total ban would have many negative effects, including protection of the cigarette market and implicit support for tobacco companies. It is possible to target advertising at existing smokers where the benefits are potentially huge and the risks minimal. It is inappropriate to apply Article 13 of the FCTC (Tobacco advertising, promotion and sponsorship) to these products.

## Statement from specialists in nicotine science and public health policy

7. *It is inappropriate to apply legislation designed to protect bystanders or workers from tobacco smoke to vapour products.* There is no evidence at present of material risk to health from vapour emitted from e-cigarettes. Decisions on whether it is permitted or banned in a particular space should rest with the owners or operators of public spaces, who can take a wide range of factors into account. Article 8 of the FCTC (Protection from exposure to tobacco smoke) should not be applied to these products at this time.
8. *The tax regime for nicotine products should reflect risk and be organised to create incentives for users to switch from smoking to low risk harm reduction products.* Excessive taxation of low risk products relative to combustible tobacco deters smokers from switching and will cause more smoking and harm than there otherwise would be.
9. *WHO and national governments should take a dispassionate view of scientific arguments, and not accept or promote flawed media or activist misinterpretations of data.* For example, much has been made of 'gateway effects', in which use of low-risk products would, it is claimed, lead to use of high-risk smoked products. We are unaware of any credible evidence that supports this conjecture. Indeed, similar arguments have been made about the use of smokeless tobacco in Scandinavia but the evidence is now clear that this product has made a significant contribution to reducing both smoking rates and tobacco-related disease, particularly among males.
10. *WHO and parties to the FCTC need credible objective scientific and policy assessments with an international perspective.* The WHO Study Group on Tobacco Product Regulation (TobReg) produced a series of high quality expert reports between 2005 and 2010. This committee should be constituted with world-class experts and tasked to provide further high-grade independent advice to the WHO and Parties on the issues raised above.

The potential for tobacco harm reduction products to reduce the burden of smoking related disease is very large, and these products could be among the most significant health innovations of the 21<sup>st</sup> Century – perhaps saving hundreds of millions of lives. The urge to control and suppress them as tobacco products should be resisted and instead regulation that is fit for purpose and designed to realise the potential should be championed by WHO. We are deeply concerned that the classification of these products as tobacco and their inclusion in the FCTC will do more harm than good, and obstruct efforts to meet the targets to reduce non-communicable disease we are all committed to. We hope that under your leadership, the WHO and FCTC will be in the vanguard of science-based, effective and ethical tobacco policy, embracing tobacco harm reduction.

We would be grateful for your considered reaction to these proposals, and we would like to request a meeting with you and relevant staff and a small delegation of signatories to this letter. This statement and any related information will be available on the Nicotine Science and Policy web site (<http://nicotinepolicy.net>) from 29 May 2014.

Yours sincerely,

## Statement from specialists in nicotine science and public health policy

### Signatories this statement at 26 May 2014

#### **Professor David Abrams**

Professor of Health Behavior and Society.  
The Johns Hopkins Bloomberg School of  
Public Health. Maryland. USA.  
Professor of Oncology (adjunct).  
Georgetown University Medical Center,  
Lombardi Comprehensive Cancer Center.  
Washington DC.  
United States of America

#### **Professor Tony Axéll**

Emeritus Professor Geriatric Dentistry  
Consultant in Oral Medicine  
Sweden

#### **Professor Pierre Bartsch**

Respiratory physician,  
Faculty of Medicine  
University of Liège  
Belgium

#### **Professor Linda Bauld**

Professor of Health Policy  
Director of the Institute for Social Marketing  
Deputy Director, UK Centre for Tobacco  
and Alcohol Studies  
University of Stirling  
United Kingdom

#### **Professor Ron Borland**

Nigel Gray Distinguished Fellow in Cancer  
Prevention at Cancer Council Victoria  
Professorial Fellow School of Population  
Health and Department of Information  
Systems  
University of Melbourne,  
Australia

#### **Professor John Britton**

Professor of Epidemiology;  
Director, UK Centre for Tobacco & Alcohol  
Studies,  
Faculty of Medicine & Health Sciences  
University of Nottingham,  
United Kingdom

#### **Associate Professor Chris Bullen**

Director, National Institute for Health  
Innovation  
School of Population Health,  
University of Auckland,  
New Zealand

#### **Professor Emeritus André Castonguay**

Faculty of Pharmacy  
Université Laval,  
Quebec,  
Canada.

#### **Dr Lynne Dawkins**

Senior Lecturer in Psychology,  
Co-ordinator: Drugs and Addictive  
Behaviours Research Group  
School of Psychology,  
University of East London,  
United Kingdom

#### **Professor Ernest Drucker**

Professor Emeritus  
Department of Family and Social Medicine,  
Montefiore Medical Center/Albert Einstein  
College of Medicine  
Mailman School of Public Health  
Columbia University  
United States of America

#### **Professor Jean François Etter**

Associate Professor  
Institut de santé globale,  
Faculté de médecine,  
Université de Genève,  
Switzerland

#### **Dr Karl Fagerström**

President, Fagerström Consulting AB,  
Vaxholm,  
Sweden

#### **Dr Konstantinos Farsalinos**

Researcher, Onassis Cardiac Surgery  
Center, Athens, Greece  
Researcher, University Hospital  
Gathuisberg, Leuven,  
Belgium

#### **Professor Antoine Flahault**

Directeur de l'Institut de Santé Globale  
Faculté de Médecine, Université de  
Genève, Suisse/ Institute of Global Health,  
University of Geneva, Switzerland  
Professor of Public Health at the Faculté  
de Médecine, Université Paris Descartes,  
Sorbonne Paris Cité,  
France

## Statement from specialists in nicotine science and public health policy

### **Dr Coral Gartner**

Senior Research Fellow  
University of Queensland Centre for  
Clinical Research  
The University of Queensland,  
Australia

### **Dr Guillermo González**

Psychiatrist  
Comisión de Rehabilitación en Enfermedad  
Mental Grave  
Clínica San Miguel  
Madrid,  
Spain

### **Dr Nigel Gray**

Member of Special Advisory Committee on  
Tobacco Regulation of the World Health  
Organization  
Honorary Senior Associate  
Cancer Council Victoria  
Australia

### **Professor Peter Hajek**

Professor of Clinical Psychology and  
Director, Health and Lifestyle Research  
Unit  
UK Centre for Tobacco and Alcohol  
Studies  
Wolfson Institute of Preventive Medicine,  
Barts and The London School of Medicine  
and Dentistry Queen Mary University of  
London,  
United Kingdom

### **Professor Wayne Hall**

Director and Inaugural Chair, Centre for  
Youth Substance Abuse Research  
University of Queensland  
Australia

### **Professor John Hughes**

Professor of Psychology, Psychiatry and  
Family Practice  
University of Vermont  
United States of America

### **Professor Martin Jarvis**

Emeritus Professor of Health Psychology  
Department of Epidemiology & Public  
Health  
University College London,  
United Kingdom

### **Professor Didier Jayle**

Professeur d'addictologie  
Conservatoire National des Arts et Métiers  
Paris,  
France

### **Dr Martin Juneau**

Directeur, Direction de la Prévention  
Institut de Cardiologie de Montréal  
Professeur Titulaire de Clinique  
Faculté de Médecine,  
Université de Montréal,  
Canada

### **Dr Michel Kazatchkine**

Member of the Global Commission on Drug  
Policy  
Senior fellow, Global Health Program,  
Graduate institute, Geneva,  
Switzerland

### **Professor Demetrios Kouretas**

School of Health Sciences and Vice Rector  
University of Thessaly,  
Greece

### **Professor Lynn Kozlowski**

Dean, School of Public Health and Health  
Professions,  
Professor of Community Health and Health  
Behavior,  
University at Buffalo,  
State University of New York,  
United States of America

### **Professor Eva Králiková**

Institute of Hygiene and Epidemiology  
Centre for Tobacco-Dependence  
First Faculty of Medicine  
Charles University in Prague and General  
University Hospital in Prague,  
Czech Republic

### **Professor Michael Kunze**

Head of the Institute for Social Medicine  
Medical University of Vienna,  
Austria

### **Dr Murray Laugesen**

Director  
Health New Zealand, Lyttelton,  
Christchurch,  
New Zealand

## Statement from specialists in nicotine science and public health policy

### **Dr Jacques Le Houezec**

Consultant in Public Health, Tobacco dependence, Rennes, France  
Honorary Lecturer, UK Centre for Tobacco Control Studies, University of Nottingham, United Kingdom

### **Dr Kgosi Letlape**

President of the Africa Medical Association  
Former President of the World Medical Association  
Former Chairman of Council of the South African Medical Association  
South Africa

### **Dr Karl Erik Lund**

Research director  
Norwegian Institute for Alcohol and Drug Research, Oslo, Norway

### **Dr Gérard Mathern**

Président de l'Institut Rhône-Alpes de Tabacologie  
Saint-Chamond, France

### **Professor Richard Mattick**

NHMRC Principal Research Fellow  
Immediate Past Director NDARC (2001-2009)  
National Drug and Alcohol Research Centre (NDARC)  
Faculty of Medicine  
The University of New South Wales, Australia

### **Professor Ann McNeill**

Professor of Tobacco Addiction  
Deputy Director, UK Centre for Tobacco and Alcohol Studies  
National Addiction Centre  
Institute of Psychiatry  
King's College London, United Kingdom

### **Dr Hayden McRobbie**

Reader in Public Health Interventions, Wolfson Institute of Preventive Medicine, Queen Mary University of London, United Kingdom

### **Dr Anders Milton**

Former President of the Swedish Red Cross  
Former President and Secretary of the Swedish Medical Association  
Former Chairman of the World Medical Association  
Owner & Principal Milton Consulting, Sweden

### **Professor Marcus Munafò**

Professor of Biological Psychology  
MRC Integrative Epidemiology Unit at the University of Bristol  
UK Centre for Tobacco and Alcohol Studies  
School of Experimental Psychology  
University of Bristol, United Kingdom

### **Professor David Nutt**

Chair of the Independent Scientific Committee on Drugs (UK)  
Edmund J Safra Professor of Neuropsychopharmacology  
Head of the Department of Neuropsychopharmacology and Molecular Imaging  
Imperial College London, United Kingdom

### **Dr Gaston Ostiguy**

Professeur agrégé  
Directeur de la Clinique de cessation tabagique  
Centre universitaire de santé McGill (CUSM)  
Institut thoracique de Montréal, Canada

### **Professor Riccardo Polosa**

Director of the Institute for Internal Medicine and Clinical Immunology, University of Catania, Italy.

### **Dr Lars Ramström**

Director  
Institute for Tobacco Studies  
Täby, Sweden

## Statement from specialists in nicotine science and public health policy

### **Dr Martin Raw**

Special Lecturer  
UK Centre for Tobacco and Alcohol  
Studies  
Division of Epidemiology and Public Health  
University of Nottingham,  
United Kingdom

### **Professor Andrzej Sobczak**

Department of General and Inorganic  
Chemistry,  
Faculty of Pharmacy and Laboratory  
Medicine,  
Medical University of Silesia, Katowice,  
Poland  
Institute of Occupational Medicine and  
Environmental Health  
Sosnowiec,  
Poland

### **Professor Gerry Stimson**

Emeritus Professor, Imperial College  
London;  
Visiting Professor, London School of  
Hygiene and Tropical Medicine  
United Kingdom

### **Professor Tim Stockwell**

Director, Centre for Addictions Research of  
BC  
Professor, Department of Psychology  
University of Victoria, British Columbia,  
Canada

### **Professor David Sweanor**

Adjunct Professor, Faculty of Law,  
University of Ottawa  
Special Lecturer, Division of Epidemiology  
and Public Health,  
University of Nottingham,  
United Kingdom

### **Professor Umberto Tirelli**

Director Department of Medical Oncology  
National Cancer Institute of Aviano  
Italy

### **Professor Umberto Veronesi**

Scientific Director  
IEO Istituto Europeo di Oncologia  
Former Minister of Health,  
Italy

### **Professor Kenneth Warner**

Avedis Donabedian Distinguished  
University Professor of Public Health  
Professor, Health Management & Policy  
School of Public Health  
University of Michigan  
United States of America

### **Professor Robert West**

Professor of Health Psychology and  
Director of Tobacco Studies  
Health Behaviour Research Centre,  
Department of Epidemiology & Public  
Health,  
University College London  
United Kingdom

### **Professor Dan Xiao**

Director of Department Epidemiology  
WHO Collaborating Center for Tobacco or  
Health  
Beijing Institute of Respiratory Medicine,  
Beijing Chao-Yang Hospital,  
China

### **Dr Derek Yach**

Former Executive Director, Non-  
Communicable Diseases  
Former Head of Tobacco Free Initiative,  
World Health Organisation (1995-2004)  
Senior Vice President Vitality Group plc  
Director, Vitality Institute for Health  
Promotion  
United States of America